As I said, we're going to be delayed coming to market. The good thing about this is that there was an export clause negotiated as part of CETA. It is in the bill. That mitigates some of the impact. If that is done properly, we're going to continue to push very hard to get investment.
I would say, going forward, that when Canada negotiates future trade agreements, there should be less emphasis given to extending intellectual property protection, which seems to be the sole focus of pharmaceutical trade agreements. If we could have more attention paid to regulatory harmonization and convergence, that would allow us, like the agricultural people, to ensure that our product meets standards abroad and this would facilitate exports. That would be a real benefit to our sector.
We would recommend going forward that more attention be given to other aspects of the pharmaceutical industry, rather than just patent protection.